Osiris Therapeutics (OSIR) Misses Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Price: $18.99 --0%
Financial Fact:
Income from operations: 310K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Income from operations: 310K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Osiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of ($0.04), $0.20 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $13.3 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- UBS Reiterates Buy Rating on Expeditors Int'l (EXPD)
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
